Background: Although biotin interferences in TSH, FT3, FT4, and other biotinylated antibody-based assays manufactured by Roche Diagnostics have been well studied, there are relatively few reports on biotin interference in biotin-based assays manufactured by other companies. We investigated biotin interferences in TSH, FT4, and FT3 assays based on the LOCI (luminescent oxygen channeling assay) technology using the Dimension Vista 1500 analyzer (Siemens).
| INTRODUC TI ON
Biotin (vitamin B7) previously known as vitamin H is an essential vitamin which acts as a coenzyme for carboxylase reactions in gluconeogenesis, fatty acid synthesis, and amino acid catabolism. Therefore, biotin is essential for life. Biotin also has a favorable safety profile because it is a water-soluble vitamin. The daily recommended allowance of biotin is only 30 microgram but taking biotin supplement in dosage of 5-10 mg/d is popular for healthy hair, nail, and skin. As a result, approximately 15%-20% Americans regularly takes biotin supplement. Moreover, patients with congenital biotin deficiency may receive biotin supplementation of 40-100 mg/d as a part of therapy. In addition, very high dosage of biotin (300 mg or higher daily) may be used for treating multiple sclerosis and demyelinating pathology. 1 In general, serum biotin levels in individuals taking no biotin supplement vary from 0.4 to 1.2 ng/mL. 2 Grimsey et al 3 studied
serum biotin levels after volunteers consumed 5, 10, or 20 mg biotin and reported that serum biotin levels after taking 5 mg supplement/d varied from 10 to 73 ng/mL. However, after taking 20 mg biotin per day the observed serum biotin levels ranged from 80 to 355 ng/mL. As expected, serum biotin levels would be much higher after taking biotin in pharmaceutical dosages such as 100 mg or 300 mg daily. The plasma biotin concentrations varied from 700 to 900 ng/mL when subjects ingested a single dose of 300 mg biotin supplement, and blood was drawn 2 hour after taking the supplement. Interference of biotin in immunoassays is dose-dependent. Most reports deal with the wrong diagnosis of hyperthyroidism due to elevated FT4 (free thyroxine), FT3 (free triiodothyronine) but falsely lower TSH (thyroid-stimulating hormone) value due to biotin interference using immunoassays marketed by Roche or Beckman. [6] [7] [8] [9] However, the TSH, FT3, and FT4 assays based on the LOCI technology and marketed by Siemens also utilize biotinylated antibody. We studied biotin interference in these assays and also the possibility of identifying such interference by dilution of specimens. We selected TSH, FT3, and FT4 assays for this study because these are most commonly ordered thyroid function tests in our hospital. Moreover, FT3
and FT4 are active forms of thyroid hormones but total T3 represents mostly protein-bound inactive form. Here, we report our findings.
| MATERIAL S AND ME THODS
Biotin was purchased from Sigma Chemical Company (St. Louis, MO), and a standard stock solution of biotin (0.1 mg/mL) was prepared in phosphate buffer saline. Then, this stock solution was diluted to prepare two working solutions (1 μg/mL and 10 μg/ mL). The TSH, FT3, and FT4 assays based on the LOCI (luminescent oxygen channeling assay) technology were purchased from Siemens, and assays were run on Dimension Vista 1500 ana- Four serum pools were prepared by combining specimens where physicians ordered thyroid panel (TSH, FT4, and FT3). Two serum pools were prepared using specimens with high TSH concentrations while two pools were prepared from patients with normal TSH concentrations. Serum pool four containing normal TSH concentration was prepared 3 months after initial study in order to investigate reproducibility of our original data using assay kits of different lot numbers. Serum pools were prepared by combing deidentified leftover specimens from patients after performing all tests ordered by physicians and saving these specimens at 4°C for 1 week as per IRB guidelines. These specimens would have otherwise been discarded.
In the first set of experiments, aliquots of serum pool one (normal TSH) and serum pool two (elevated TSH) were supplemented with various amounts of biotin (50-1200 ng/mL) followed by determination of TSH, FT3, and FT4 using the Dimension Vista 1500
analyzer. Each measurement was performed in duplicate, and the mean value was calculated. In the second set of experiments, aliquots of serum pool three (elevated TSH) were supplements with biotin (100-1200 ng/mL), and again, TSH, FT4, and FT3 values were measured using the Dimension Vista 1500 analyzer. However, we also determined TSH, FT3, and FT4 concentrations in these aliquots after 1:3 dilution to investigate possible nonlinearity due to biotin interference. Specimens were diluted using dilution solution provided by the Siemens for dilution of TSH specimens. Again, all measurements were performed in duplicate. We also programmed the instrument to take into account the dilution and to calculate expected values.
Three months after initial study, we prepared serum pool four and supplemented aliquots of the serum pool with various amounts of biotin (50-1200 ng/mL) followed by determination of TSH, FT3, and FT4 using the Dimension Vista 1500 analyzer.
However, all reagents used for measuring TSH, FT3, and FT4 had different lot numbers than reagent kits that we used for the initial studies. The objective was to verify reproducibility of our original results.
| RE SULTS
We considered more than 10% difference as analytically significant but 20% difference as clinically significant as proposed by the College of American Pathologists (CAP). We observed more than 10% difference in the FT3 concentration at serum biotin level of only 50 ng/mL while significant clinical interference (more than 20% difference) was observed at serum biotin level of 100 ng/mL.
For example, in serum pool one, FT3 value was increased from 2.42 pg/mL to 3.02 pg/mL in the presence of 100 ng/mL biotin, a 25% increase in analyte concentration. In contrast, the FT4 assay showed clinically significant difference in serum biotin concentration of 500 ng/mL. The TSH assay was also impacted at 500 ng/ mL serum biotin concentration. For example, in serum pool two, TSH value was reduced from 10.70 μIU/mL to 7.93 μIU/mL in the presence of 500 ng/mL of serum biotin concentration, a 26% | 3 of 5 DASGUPTA AnD BOURGEOIS reduction in TSH level (Table 1) . In order to verify reproducibility of our initial data, we prepared serum pool four 3 months after the initial study and repeated our original experiments as described for serum pool one and two. We observed similar results which are represented graphically in Figure 1 .
We studied possible nonlinearity of dilution to identify biotin interference and obtained best result using 1:3 dilution. We also diluted original serum pool (pool three) to investigate potential matrix effect during dilution. We only observed significant matrix effect on FT3 level as the original value in serum pool three was increased from 2.12 pg/mL to 2.44 pg/mL, a 13% positive bias following dilution.
However, with 1:4 dilution matrix bias was more significant (data not shown).
We observed nonlinearity during dilution but such dilution did not eliminate biotin interference due to vulnerability of the FT3 assay to biotin interference. For example, in the presence of 500 ng/mL of biotin, TSH value was reduced from 9.08 μIU/mL to 7.12 μIU/mL (21.5% reduction) but calculated TSH value using 1:3 dilution was 8.42 μIU/mL, which represented only 7.2% reduction, a not clinically significant difference. However, for FT3, the calculated value in the presence of 500 ng/mL after 1:3 dilution was 6.12 pg/mL which was 2.5-fold higher than FT3 value of 2.12 pg/ mL in the original pool (Table 2) . Nevertheless, this calculated FT3 value was significantly lower than 16.33 pg/mL, a value observed without any dilution, indicating that nonlinearity during dilution is an indicator of biotin interference (or any other interference). TA B L E 1 Biotin interference in thyroid-stimulating hormone (TSH), free triiodothyronine (FT3), and free thyroxine (FT4) assays using Vista 1500 analyzer 
| D ISCUSS I ON
We selected biotin concentrations that represent serum biotin levels after taking biotin supplement as well as pharmaceutical dosage of biotin (300 mg/d). The FDA report indicates that serum biotin level can reach up to 1200 ng/mL, 10 which is also the highest biotin level chosen for our study. Trambus et al 11 reported that some
Roche assays, such as troponin T, TSH, and antithyroid antibodies,
were extremely sensitive to the lower concentrations of biotin (15.6 and 31.3 ng/mL), whereas the majority of assays were relatively resistant. However, at concentrations ≥500 ng/mL, all assays showed significant interference from biotin. Ali et al 12 studied biotin interference in vitro in various biotin-based immunoassays on Vitros 5600
analyzer and observed that biotin at 6.25 ng/mL affected TSH assay causing more than 20% negative bias. Serum biotin level after taking 5 mg supplement/day varied from 10 to 73 ng/mL. 3 Therefore, even taking 5 mg biotin, TSH measurement using Vitros 5600 analyzer may be affected.
Li et al investigated the effect of biotin on performance of hormone and nonhormone assays using six healthy adults (two women and four men; mean age: 38 years) who ingested 10 mg biotin for 7 days. The authors reported that biotin ingestion was associated with falsely decreased TSH level but falsely increased FT3 and FT4 levels using Roche assays The interference in TSH measurement was more significant using Vitros 5600 analyzer (Ortho Clinical Diagnosis), but the TSH assay on the Dimension Vista analyzer was not affected.
However, the FT3 assay on the Dimension Vista analyzer was affected. 13 In another study, the authors resolved erroneous TSH, FT3, and FT4 values obtained by Roche assays by using ADVIA Centaur assays (Siemens Diagnostics) which are not biotin-based. 14 Our study indicates that the FT3 assay based on the LOCI technology is most vulnerable to biotin interference where interference was observed at serum biotin concentration of only 100 ng/mL. This concentration may be achieved in people taking 10 mg biotin supplement per day. However, TSH and FT4 assays based also on the LOCI technology are less susceptible to biotin interference. Based on in vivo study, in order to reach serum biotin concentration 500 ng/mL, a person needs to take at least 100 mg of biotin. 4 Recent studies indicate that high dose biotin 19 Although biotin interference in biotin-based immunoassays can be completely eliminated by the pretreatment of specimen with streptavidin-coated microparticle to deplete biotin present in specimens, this is a manual, time-consuming process. 20 However, best approach to eliminate biotin interference is to use an alternative assay platform that does not use biotin in assay design. Currently, most assays marketed by Abbott Laboratories do not use biotin in assay design and only four assays that are biotinbased showed no biotin interference. DiaSorin Inc. also has no assay that is biotin-based. 21 We conclude that the FT3 assay on the Dimension Vista analyzer is vulnerable to biotin interference (threshold: 100 ng/mL) but TSH and FT4 assays on the same analyzer are affected at serum biotin concentration of 500 ng/mL or higher.
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